Insider filing
Traded Oct 7 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Signed Sep 29, 2026 · Updated Sep 29, 2026
The Department of Health and Human Services has committed $72.2M to Leidos so far. It runs until Sep 28, 2031.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
$72,167,416
Actual federal dollars obligated to date on this award
$72,167,416
A maximum, not earned revenue
$1.35B across 10 awards
Obligations to date on awards newly signed in the last 12 months, mapped to this company
87.4% from the largest awarding agency
Share of T12M mapped obligations
#6 of 10 mapped awards by obligations
Within the awards OQRO has ingested
Not available
No annual revenue figure from the company's SEC filings yet
exact identifier
Exact identifier > verified alias > manual override
Insider filing
Traded Oct 7 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Sep 30 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Sep 30 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's last weighty Form 8-K report up to this date: reported its results, 56 days earlier (Aug 4, 2026). The first one after it: changed a top executive or board member, 2 days later (Oct 1, 2026).